http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11377465-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dfd59fccc523023cb1be2a2ff29e60c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1195105daef381efe9b92af8e8a56a63 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H17-02 |
| filingDate | 2019-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b022c0137c0238e9e8df2270ce00a9db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f2aea01309b9b97a63616b3df361bbe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8e4cba53d4728d561990b69da190d47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4cccd0989a7f004a14c9a6fb0e51f1c |
| publicationDate | 2022-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-11377465-B2 |
| titleOfInvention | Pyranoglucose-substituted pyrazole compound, preparation method thereof and application thereof |
| abstract | A pyranoglucose-substituted pyrazole compound, used as a pharmaceutical intermediate, having the structural formula represented by formula (9c). The present invention further relates to an intermediate compound represented by formula (10c) or a salt thereof. The present invention further relates to a preparation method of the aforementioned intermediate compound and a method of using the same to prepare an SGLT inhibitor. By means of the novel key intermediate, the preparation technique of an SGLT inhibitor is greatly simplified. In addition, because the intermediate can be precipitated in the form of a salt and is easy to purify, the purity of the SGLT inhibitor is significantly increased, compared with the original preparation pathway (crude product purity can reach 99% or more). (I) |
| priorityDate | 2018-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 160.